ETIDIOH - NEW

  Antimicrob Agents Chemother MENG X, Zhang C, Wang X, Shi J, et al A branched peptide targets virus and host to block influenza virus and rhinovirus entry. Antimicrob Agents Chemother. 2025 Jun 25:e0002425. doi: 10.1128/aac.00024. PubMed           Abstract available Antiviral Res HUSSAIN S, Meijer A, Govorkova EA, Dapat C, et al Global update on the susceptibilities of influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2020-2023. Antiviral Res. 2025 Jun 24:106217. doi: 10.1016/j.antiviral.2025.106217. PubMed           Abstract available Biochemistry PANKRATOVA Y, Hong M Side Chain Structures of the Proton-Selective Histidine and Gating Tryptophan in Influenza BM2 Reveal Both Conservation and Variation of the Proton Conduction Mechanism. Biochemistry. 2025 Jun 24. doi: 10.1021/acs.biochem.5c00242. PubMed          ...

Abstract The ongoing spread of highly pathogenic avian influenza H5N1 clade 2.3.4.4b virus in animals and occasional spillover to humans have raised concerns about a potential H5N1 pandemic. Although recent studies have shown that pre-existing human antibodies can recognize H5N1 neuraminidase , there is a lack of molecular understanding of how this cross-reactivity develops. Using a phage display antibody library derived from 245 healthy donors , this study isolates an antibody, known as HB420 , that cross-reacts with the neuraminidases of human H3N2 and avian H5N1 clade 2.3.4.4b viruses and confers protection in vivo. Cryo-EM analysis shows that HB420 targets the neuraminidase active site by mimicking sialic acid binding through a single Asp residue. Additionally, the inferred germline of HB420 is N2-specific but acquires cross-reactivity to H5N1 neuraminidase through somatic hypermutations . Overall, our findings provide insights into how neuraminidase antibody evolves breadth, which...

Highlights •  Antiviral susceptibility to NA inhibitors and PA inhibitor baloxavir was determined for seasonal and zoonotic influenza viruses circulating globally during 2020–2023. •  Low global frequencies (0.1-0.2%) of seasonal influenza viruses with reduced or highly reduced inhibition by NAI inhibitors were observed as in previous years. •  Low global frequencies of seasonal influenza viruses (∼ 0.1%) with reduced susceptibility to baloxavir were observed, with the rate in Japan elevated (3.3%) in 2022–2023, as has been seen previously. •  For zoonotic viruses, 2.7% contained genetic markers associated with reduced or highly reduced inhibition to NA inhibitors and none contained markers associated with reduced susceptibility for baloxavir. •  For the treatment of influenza , NA inhibitors and baloxavir remain suitable. ABSTRACT Antiviral susceptibility of influenza viruses is monitored by the World Health Organization Global Influenza Surveillance and Respon...

  Ann Intern Med BILINSKI A, Emanuel N, Ciaranello A Sins of Omission: Model-Based Estimates of the Health Effects of Excluding Pregnant Participants From Randomized Controlled Trials. Ann Intern Med. 2025 Apr 29. doi: 10.7326/ANNALS-24-00689. PubMed           Abstract available YEK C, Mancera AG, Diao G, Walker M, et al Impact of the COVID-19 Pandemic on Antibiotic Resistant Infection Burden in U.S. Hospitals : Retrospective Cohort Study of Trends and Risk Factors. Ann Intern Med. 2025 Apr 29. doi: 10.7326/ANNALS-24-03078. PubMed           Abstract available Cell PEKAR JE, Lytras S, Ghafari M, Magee AF, et al The recency and geographical origins of the bat viruses ancestral to SARS-CoV and SARS-CoV-2. Cell. 2025;188:3167-3183. PubMed           Abstract available Drug Saf ABATE A, Poncato E, Barbieri MA, Powell G, et al Off-the-Shelf Large Language Models for Caus...

Abstract We conducted genomic surveillance of seasonal influenza during the 2022-2023 northern hemisphere flu season on a large university setting in Southwest Arizona USA to understand the diversity, evolution, and spread within a local environment and how it relates to national data. Through high-throughput sequencing and bioinformatics, we identified 100 positive samples (19%) from 516 clinical swabs collected at the student health clinic. We observed a dominance of subtype A(H3N2) which was consistent nationally for the 2022-2023 season. However, we found stark differences when examining subtype-specific H3 clades , which included an early dominance of clade 2a.3a.1 variants contrasting from country-level data in which 2b variants were most abundant. These variants might have contributed to the early seasonal peak on campus which lagged national trends by one month. We used phylodynamics to understand the timing, source, and impact of clade-specific introductions on campus and obse...

  Antiviral Res MARTINEZ-GZEGOZEWSKA Y, Rasmussen L, Nebane NM, McKellip S, et al High-throughput screening for identification of Influenza A inhibitors using a cell-based immunofluorescence assay. Antiviral Res. 2025 Jun 6:106209. doi: 10.1016/j.antiviral.2025.106209. PubMed           Abstract available Arch Virol LU Y, Ni J, Huang S, Guo Y, et al Epidemiological characteristics of human parainfluenza virus infections and phylogenetic analysis of human parainfluenza virus type 3 isolated from children with respiratory tract infections from 2020 to 2022 in Zhejiang, China. Arch Virol. 2025;170:157. PubMed           Abstract available JIN H, Cho YR, Jung YT Single-particle quantification of SARS-CoV-2 virus-like particles using flow virometry. Arch Virol. 2025;170:149. PubMed           Abstract available Cell STEVENS J, Culberson E, Kinder J, Ramiriqui A, et al Mic...

Key Points -- Question:   In adults with influenza requiring admission to hospital, is oseltamivir treatment within the first 2 days of admission, when compared with supportive care without oseltamivir, associated with a decreased risk of death in hospital? -- Findings:  In this cohort study of 11 073 patients hospitalized with influenza, oseltamivir treatment was associated with an adjusted risk reduction of 1.8% for in-hospital mortality when compared with supportive care. -- Meaning:  The findings of this study support current guidelines that recommend oseltamivir treatment for patients admitted to hospital with influenza; clinical trials should be conducted to generate better quality evidence. Abstract Importance    Current guidelines recommend oseltamivir treatment for all patients hospitalized with influenza, but this guidance is based on suboptimal evidence. Objective    To evaluate outcomes associated with oseltamivir treatment when compared wi...

  BMC Pediatr ALRASHED R, Almeshawi I, Alshammari A, Alhamoud W, et al Burden of bronchiolitis post-COVID-19 pandemic in children less than 2 years old in 2021-2024: experience from a tertiary center in Saudi Arabia. BMC Pediatr. 2025;25:453. PubMed           Abstract available BIGLARI HN, Ahmadi A, Alidousti K, Pouredalati M, et al Growth in the first two years in children born to mothers infected with COVID-19 during pregnancy: a cohort study. BMC Pediatr. 2025;25:448. PubMed           Abstract available CHENG J, Wu Y, Ma H, Tang M, et al C-reactive protein and serum amyloid A protein as complementary biomarkers in differentiating viral and bacterial community-acquired pneumonia in children. BMC Pediatr. 2025;25:445. PubMed           Abstract available J Gen Virol CAPELASTEGUI F, Goldhill DH H5N1 2.3.4.4b: a review of mammalian adaptations and risk of pandemic e...